Brief: Zynerba Pharmaceuticals Announces Positive Top Line Results From Open-Label Phase 2 Inspire Trial Of Zygel
22/06/2022 01:07
June 21 (Reuters) - Zynerba Pharmaceuticals Inc ZYNE.O :
* ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE TOP LINE
RESULTS FROM
OPEN-LABEL PHASE 2 INSPIRE TRIAL OF ZYGEL™ IN 22Q11.2 DELETION
SYNDROME
* ZYNERBA - INSPIRE TRIAL ACHIEVED STATISTICALLY SIGNIFICANT
AND
CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE IN MULTIPLE
EFFICACY ASSESSMENTS
* SAFETY DATA REINFORCE EXCELLENT TOLERABILITY PROFILE OF
ZYGEL
* CASH RUNWAY EXTENDED THROUGH END OF 2023 / EARLY 2024
Source text for Eikon: ID:nGNX1WkX8t
Further company coverage: ZYNE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zynerba Pharmaceuticals
See all newsBrief: Harmony Biosciences Completes Acquisition Of Zynerba Pharmaceuticals
Brief: Harmony Biosciences Announces Extension Of Tender Offer To Acquire Zynerba Pharmaceuticals, Inc.
Brief: Zynerba Pharmaceuticals Presents Positive Data From Phase 2 Inspire Trial
U.S. RESEARCH ROUNDUP-Easterly Government Properties, Visa, Zynerba Pharmaceuticals
Zynerba Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary